Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.

Translated title of the contribution: Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Original language	Undefined/Unknown
Pages (from-to)	667-675
Number of pages	9
Journal	European Journal of Endocrinology
Volume	162
Issue number	4
Publication status	Published - 2010

Cite this

@article{45024dddb66546dfb23f84615c59596d,

title = "Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.",

author = "M. Lafeber and A.M.E. Stades and G.D. Valk and M.J.M. Cramer and \{Teding van Berkhout\}, F. and P.M.J. Zelissen",

year = "2010",

language = "Undefined/Unknown",

volume = "162",

pages = "667--675",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.

AU - Lafeber, M.

AU - Stades, A.M.E.

AU - Valk, G.D.

AU - Cramer, M.J.M.

AU - Teding van Berkhout, F.

AU - Zelissen, P.M.J.

PY - 2010

Y1 - 2010

M3 - Article

SN - 0804-4643

VL - 162

SP - 667

EP - 675

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 4

ER -